All‐cause mortality at 30 days · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
All‐cause mortality at 5 years · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Number of participants with Variceal rebleeding episodes at 30 days · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes number of participants with Variceal rebleeding episodes at 30 days compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Reintervention Number of women with reintervention · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes number of participants with reintervention at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Irreversible shunt occlusion at 5 years · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes irreversible shunt occlusion at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Encephalopathy · people with cirrhotic portal hypertension
It is very uncertain whether surgical portosystemic shunts changes number of participants with encephalopathy at 5 years compared with transjugular intrahepatic portosystemic shunt (TIPS) (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with cirrhotic portal hypertension
1 finding from 1 review
All‐cause mortality · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes all‐cause mortality compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Serious adverse events · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes serious adverse events compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Quality of life · people with hepatosplenic schistosomiasis
1 finding from 1 review
Rebleeding · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes variceal rebleeding rate compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Encephalopathy · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes encephalopathy compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Ascites · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes ascites compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review
Any re‐intervention · people with hepatosplenic schistosomiasis
It is very uncertain whether surgical portosystemic shunts changes any re‐intervention compared with devascularisation with splenectomy (very low certainty).
1 finding from 1 review